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AH ancestral haplotype
cCD classical coeliac disease
CD coeliac disease
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CYP21B cytochrome 21B-gene
DH dermatitis herpetiformis
DNA deoxyribonucleic acid
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HFE haemochromatosis
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NK natural killer cell
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TAP1,-2 transporter associated with antigen processing 1, -2
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ABSTRACT
Gluten sensitivity or coeliac disease is a relatively common multifactorial enteropathy,
where the main environmental factor is the gluten fraction of wheat, barley and rye.
The gluten intake may cause variable symptoms in genetically predisposed
individuals, classically affecting the gastrointestinal tract but also causing e.g.
dermatological, neuronal, or autoimmune manifestations. The only confirmed genetic
susceptibility locus is HLA-DQ, located on chromosome 6. Approximately 90% of
the patients possess the HLA-DQ2 molecule encoded by the DQA1*05 and
DQB1*02 alleles and the rest of the patients carry the HLA-DQ8 encoded by the
DQA1*03 and DQB1*0302 alleles.
This thesis is composed of five studies focusing on the role of HLA genes in different
manifestations of gluten sensitivity. Firstly, a practical and economical tool for HLA
typing was developed using HLA-linked microsatellite marker alleles (I). The alleles
proved to be in strong linkage disequilibrium with certain HLA DR;DQ haplotypes
in the Finnish population. This method was used in the following studies with gluten
sensitive patients, their family members and controls.
To estimate the relative importance between genetic and non-genetic factors on
susceptibility to intestinal and dermatological manifestation of gluten sensitivity, six
monozygotic twin pairs were examined (II). The results indicated that the same
genetic background can result in variable manifestations. The probandwise
concordance for gluten sensitivity as a broad entity was surprisingly high, 0.91. No
differences in predisposing HLA haplotypes were found either in 25 sib pairs with
one having the intestinal and the other the dermatological form of the disease, or in
85 sib pairs with identical manifestation types (III). Similar results with no major
differences in HLA distribution between patients with different manifestations were
obtained for Hungarian index patients (III).
The HLA-DQ2 heterodimer is the major predisposing genetic factor for coeliac
disease, but still only a minority of DQ2 carriers at population level are affected. To
look for possible differences in DQ2 positive haplotypes, a segregation study in
families with a DQ2 homozygous parent was performed (IV). The DQ2 positive
haplotypes transmitted to affected offspring were more conserved than the non
transmitted DQ2 haplotypes; the most significant statistical difference was in the
frequency of the HLA-A*01 allele (p=0.007). To reveal additional risk factors within
the HLA region, coeliac patients without the predisposing HLA-DQ2 were collected
from a large European coeliac disease material consisting of 1008 families (V). This
study definitely confirmed that coeliac disease without the known predisposing DQ
alleles (DQA1*05, DQB1*02, or DQB1*0302) is very rare: only four (0.04%) such
patients could be found. These four patients had no similarities in their HLA alleles,
symptoms, age of onset or family history.
The present studies demonstrate that the HLA molecules DQ2 and DQ8, or either
the DQA1*05 or DQB1*02 allele predispose to both the intestinal and dermatological
manifestation of coeliac disease, and that patients without these genetic risk factors
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are very rare. Our results further suggest, that from a genetic point of view, these
two forms in fact can be regarded as different manifestations of a single disease
entity. Finally, we provided evidence that the HLA region may contain a novel non-
DQ risk factor for coeliac disease, but we were not able to pinpoint its location. As
similar results have been obtained in other HLA-associated diseases, the complexity
of the HLA-disease associations may be higher than previously assumed.
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HUMAN IMMUNOLOGY AND HLA
The immune system has a life-saving task protecting the human body from
destruction by harmful invaders such as bacteria or parasites, maintaining tolerance
to self-structures and destroying old, mutated or virulent cells. The system is partly
complete at birth, but the specificity increases throughout life as a consequence of
coming into contact with foreign antigens. The major populations of cells responsible
for the increasing specificity, so called adaptive immunity, are T and B lymphocytes,
often simplified into T and B cells.
Intestinal mucosal immunology
The gastrointestinal tract is continuously exposed to different dietary antigens,
pathogens and resident microflora. Especially the intestine has to balance between
controlling the access of potentially harmful antigens and at the same time trying to
absorb necessary nutrients. The outermost part of the intestine is a mucosa, which
covers circa 400 m2 as a single cell epithelial layer. The epithelium is spread over
villi, finger-like structures. The villus epithelium contains mainly enterocytes and
intraepithelial lymphocytes, both which reside above the basement membrane.
Under the basement membrane is lamina propria, connective tissue containing
several cell types e.g. T and B lymphocytes and dendritic cells. The villi are separated
by crypts of Lieberkühn (Fig. 1). The essential nutrients may easily pass the thin
epithelia by different transport mechanisms but the peptide antigens recognised
as foreign are mainly caught up by antigen presenting cells.
Figure 1. Epithelial layer covers intestinal
villi. The epithelium consists of enterocytes
and intraepithelial lymphocytes (IELs), mostly
cytotoxic T cells. Under the basement
membrane, in lamina propria, there are more
lymphocytes, mainly T helper cells and B
cells. The surface epithelium is continuous
with that in crypts of Lieberkühn, and
embedded in lamina propria. Picture
according to Halttunen, 2002.
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The places for T and B lymphocytes to mature are secondary lymphoid tissues, in
the intestine called Peyer’s patches. There B cells start producing antigen-specific
immunoglobulins, mainly IgA, and T lymphocytes develop into CD8+ cytotoxic T
cells or activate and differentiate into Th1 or Th2 type of CD4+ T helper cells. The
activation of T cells requires two separate signals. First is the interaction between
the T cell receptor-CD3 complex and the human leucocyte antigen (HLA) molecule
of the antigen presenting cell. The second signal is produced by costimulatory and
adhesion molecules, which encounter ligands on T cells, CD28/CD80 and CD86,
CD2/LFA-3 (leucocyte functional antigen), LFA-1/ICAM-1 (intercellular adhesion
molecule-1). The subset specific differentiation of CD4+ T cells depends on
cytokines. Interleukine (IL)-4 induces Th2 cell differentiation whereas IL-12, IL-18
and IFN-g  (interferon- g ) generates Th1 cells. The physiological difference of matured
T helper cells appear on their cytokine production; Th1 produces mainly IFN-g ,
induces inflammation and promotes cytotoxic immune responses while Th2 is
involved in B cell activation and humoral immune responses with the production of
IL-4, IL-5, IL-9 and IL-13 (1;2). The matured CD4+ T cells home from Peyer’s patches
back to lamina propria and stay there mediating specific adaptive immune defence.
The lymphocytes within the epithelial layer are mostly CD8+ cytotoxic T cells whose
cytokine profile is determined by the activation signal, mainly resulting in the
production of Th1 type cytokines.
A particular population of CD8+ T cells bears a gd  T cell receptor. In the periphery
they are rare, only about 5% of T cells, but in the gut they comprise even 10% of
intraepithelial lymphocytes (3;4;5). The mechanism they apply in the immune
response differs from that of T cells with the ‘standard’ ab  receptor. The gd  T cells
recognise stress-associated MICA and MICB molecules (6) and secrete cytokines
mediating both innate and adaptive immunity (7). They may exceptionally develop
in the gut independently of the thymus and appear in the gut wall before more
common T cells with ab  T cell receptors (8). The gd  T cells may also take part in the
genesis of oral tolerance.
Oral tolerance is a typical character of mucosal immunity. It is a systemic
unresponsiveness to peripheral antigen challenge like food antigens, thus
preventing otherwise devastating hypersensitivity reactions. The detailed
mechanisms of oral tolerance are unknown but at least T cells are known to
mediate it by active suppression or by regulatory cells, by going into anergy or
by becoming deleted (9).
Human leucocyte antigen, HLA
In T cell activation the peptide antigen is presented by the human leucocyte antigen
(HLA) molecule to the T cell receptor. The genes coding for HLA molecules are
located on chromosome 6, in special HLA region at 6p21.3.
The HLA region compasses approximately 4 Mb of DNA and it is one of the gene
richest segments within the human genome as it contains more than 200 genes.
The region is often split into three regions based on the functional characteristics of
genes within each class, named from telomeric class I, class III and class II (Fig. 2).
11REVIEW OF THE LITERATURE
The genes for classical HLA molecules are located within class I and class II region,
but many other genes involved in immune regulation are found scattered throughout
the HLA region. (10;11)
Classical HLA molecules
Major histocompatibility (MHC) molecules were first discovered in mice while
studying tissue rejections following transplantations. Hence the name. Later similar
molecules have been observed in every vertebrate from zebra fish to humans. In
man MHC is called the human leucocyte antigen, HLA. (12;13)
The molecules involved in antigen presentation to T cells are called classical HLA
molecules. They are divided into two groups: HLA-A, -B and -C are transcripted
from class I region and they present mainly endogenously synthesised peptidess
like viral or tumour peptides to CD8+ cytotoxic T cells while HLA-DR, -DQ and -DP
from class II present predominantly exogenous antigens as bacterial peptides to
CD4+ T helper cells. This functional division of peptide presentation ensures that
all deleterious antigens get proper treatment; cells with mutated DNA are destroyed
immediately by cytotoxic T cells and a specific B cell immunoglobulin repertoire is
created for exogenous antigens in addition to clearance of antigens aided by T
helper cells.
Figure 2. The map of HLA region on chromosome 6 (according to Klein and Sato, 2000).
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HLA class I molecules
Most nucleated cells express the HLA class I molecules, with exceptions such as
cells from the central nervous system, sperm, oocytes, placenta and endothelial
cells of lens. The first three-dimensional structure of an HLA class I molecule, HLA-A2
was illustrated in 1987 (14). Since then a similar structure has been observed in all
studied class I molecules (Fig. 3a).
The HLA class I molecule is composed of two polypeptide chains: an a  chain
encoded by the HLA locus and a lighter b 2-microglobulin encoded by chromosome
15. The a  chain is an integral membrane protein of approximately 43 kD in size. Its
extracellular portion has three domains of which a 1 and a 2 form the functionally
important structure: the peptide binding groove (Fig. 3c). The groove consists of
eight variable b -sheet and two a -helical structures and it is capable of binding the
peptide antigen and presenting it to T lymphocytes. Briefly, intracellular peptide
antigens are cut into peptides of 8-11 amino acids in length. They bind to the
groove and following transportation of the complex onto the cell membrane, are
presented by HLA molecules to T cells. An important feature is the extensive genetic
variation of the HLA molecules (see chapter below), which is enriched in the amino
acids forming the groove. Consequently, the exact structure of HLA molecules and
importantly their capacity to bind peptides and present them to the immune system
differ between individuals. (15)
HLA class II molecules
HLA-DR, -DQ and -DP molecules are part of the immunoglobulin superfamily like
class I molecules with related structure and function. However the distribution of
class II molecules is more limited as these integral membrane glycoproteins are
expressed mainly on professional antigen presenting cells: on B cells, macrophages
and dendritic cells and after cytokine induction on epithelial cells and fibroblasts.
The class II molecules are also heterodimers but both chains are encoded from the
HLA region, hence there are always two genes for class II molecules, such as DQA
Figure 3. Simplified illustrations of classical HLA molecules from class I region (A) and
class II region (B). A peptide binding groove with a -sheets and b -helixes of HLA-A*02
molecule (C) pictured from above (according to Bjorkman et al 1987).
b 2m = b 2-microglobulin, TM = transmembrane
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and DQB, or DPA and DPB. There can be even more genes like DRB1-DRB9, but of
those only DRB1, DRB3, DRB4 and DRB5 are functional, the others being
pseudogenes. The chains, a  and b , consist of four extracellular domains
noncovalently detached (Fig. 3b). a 1 and b 1 form a groove similar to class I
molecules with a -helixes and b -sheets. The peptide binding groove of class II
molecules differs from that of class I molecules in its ability to bind longer peptides,
starting from 13 amino acids and going even as high as 24. a 2 and b 2 domains are
membrane proximal domains supporting the peptide-binding platform. (15;16)
Nomenclature and polymorphism
Observation of leucocytes agglutinating with antisera from transfused individuals
lead to the discovery of the HLA system in the 1950’s. At the beginning, the names
of different alleles were given on the basis of serological typing. However, now with
DNA sequence data available the allele names are based on sequenced genes.
The more detailed typing methods have increased the number of different alleles
dramatically. For example, the serological HLA-A2 specificity actually includes 68
alleles (HLA-A*0201 – *0260 / www.anthonynolan.org.uk/HIG/lists/class1list.html
20.11.2002) as defined by their DNA sequence. The allele name always has the
name of the region (HLA), locus (A) and the particular group of alleles (*02), usually
also the name of the specific allele, such as HLA-A*0201 which means allele 01 of
the HLA-A*02 group (Table 1). In addition, there can be information of silent mutations
(fifth and sixth digits) or mutations outside of the coding regions (seventh and
eighth digits). Exceptional HLA gene expression is indicated by letters: N for null
allele, L for low expressed allele, S for soluble secreted molecule, C for cytoplasmic
product and A for allele with an aberrant expression. In cases where numbers
exceed 99, a second number series will be introduced (17). An attempt to simplify
scientific text has actually increased confusion, as often the HLA class II heterodimers
are called by their serological equivalents instead of writing both alleles encoding
molecules e.g. DQA1*0501 and DQB1*0201 form a serological specificity called
DQ2, which is also the name for the molecule encoded by DQA1*0201 and
DQB1*0202.
Table 1. The nomenclature of the HLA alleles is based on the sequenced data and HLA
gene expression. First comes the name of the region followed by the particular locus with
indication of the allele group. The specific allele is identified by the third and the fourth
numbers which may be followed by a mark for aberrant gene expression (see text) or for a
synonymous mutation (fifth and sixth numbers) or for a mutation outside of the coding
region (seventh and eighth numbers).
Nomenclature Indication
HLA gene region
HLA-A particular locus
HLA-A*02 group of alleles
HLA-A*0201 specific allele
HLA-A*020101 allele with synonymous mutation
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Classical HLA genes are among the most polymorphic ones in humans (18). At least
250 HLA-A, 488 HLA-B, 118 HLA-C, 387 HLA-DRB, 53 HLA-DQB1, 99 HLA-DPB1
alleles had been identified world-wide by August 2002 (www.anthonynolan.com/HIG/
30.7.2002). The polymorphism is created by point mutations, gene conversions
and recombinations. At the amino acid level the most important changes take place
in the hypervariable regions encoding the amino acids which form the peptide
binding groove. These mutated hypervariable regions allow binding and presentation
of new and different peptides to T cells increasing the potential of the immune
response. The mutation rate within the HLA genes is relatively high (10-8)(19) and
interestingly, very few mutations within the coding region appear to be silent
compared to the mutations on non-coding regions. This speaks in favour of
evolutionary force towards amino acid variation.
The huge number of different alleles gives rise to a variety of HLA combinations,
and thus to different and versatile immune responses between individuals. The
diversity is even increased as a typical feature with HLA alleles is the codominant
expression, meaning that the alleles from both parents are expressed at the same
time, giving a minimum number of twelve different classical HLA molecules in a
heterozygous person. The variety is also increased by HLA-D molecules encoded
in trans e.g. DQA1 inherited from the mother is combined with paternal DQB1. In
addition, individuals with DRB1*03, *11, *12, *13 or *14 usually have an expressed
allele in the DRB3 locus, those with DRB1*04, *07 or *09 express the DRB4 locus
and those with DRB1*15 or *16 alleles express the DRB5 locus (Fig. 4). The peptides
encoded by the DRB3, DRB4 and DRB5 genes combine with the DRA protein to
form DR52, DR53 or DR51 molecules, respectively. (20)
Annual meetings of the WHO Nomenclature Committee for Factors of the HLA
System, monthly updates in journals as well as online, help researchers to keep up
to date with HLA nomenclature. The founding of new alleles is important knowledge
especially for clinical tissue typing laboratories, where the matching of transplants
is carried out. Since the importance of HLA typing was originally demonstrated by
Patel et al (1968) (21) for the selection of kidney donors, all patient - donor pairs are
Figure 4. Expression of DRB3, DRB4 and DRB5 loci depends on the individual DRB1 alleles.
People with DRB1*03, *11, *12, *13  or *14  allele may also express allele in the DRB3 locus
encoding the DR52 molecule. Individuals with DRB1*04, *07 or *09 may have the DRB4
locus encoding the DR53 molecule and those with DRB1*15 or*16 alleles expressing the
DRB5 have the DR51 molecule.
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now routinely matched for their HLA-A, -B, and -DR alleles for solid organ
transplantation. For stem cell transplantation the requirements are much stricter
and basically the matching is done for every classical HLA loci.
Other genes of the HLA region
Soon after genomic cloning of the HLA gene region (22) it was clear that there is a
high number of other genes located near and between the classical HLA genes.
Many of those genes are involved in the immune regulation in addition to the classical
HLA genes. Some of them are directly involved in maturation of HLA class I or II
molecules such as TAP1 and TAP2 (transporter associated with antigen processing
1 and -2) presenting antigens to class I molecules and LMP2 and LMP7 (low
molecular weight protein 2 and -7), which are parts of proteasomes. Proteasomes
degrade antigens into peptides, which bind to the class I molecules. Tapasin from
class II anchors the class I heterodimers into TAP1 and TAP2 to wait for antigen
before moving to the surface. Other molecules encoded on the HLA region and
aiding class II heterodimers to mature are e.g. HLA-DM which facilitates antigen
binding to class II molecules and its negative regulator HLA-DO. (20)
The HLA region also contains genes for the complement components C2, C4 and
factor B, for the cytokines TNFa (tumor necrosis factor), LTA and LTB (lymphotoxin
A and -B) and for the heat shock protein HSP70. Cells expressing HLA-E or HLA-G
(mainly on placental cells) derived from class I region are not killed by NK cells,
while members of the MIC gene family, MICA and MICB (MHC class I chain related
gene A and B), activate killing. MICs have a similar structure to HLA class I molecules
but without b 2-microglobulin. They have no capacity for antigen presentation but
instead they serve as a ligand to NK cells, g d  T cells and some CD8+ T cells
(23;24). Another molecule structurally related to class I molecules, is HFE
(haemochromatosis), which is responsible for iron metabolism. Its gene is located
in the extended HLA region, 4,6 Mb telomeric from the classical HLA border, but
considered as an HLA molecule because of its structural similarity. Another gene
not even structurally related to HLA is the cytochrome 21B-gene, CYP21B, whose
product controls intermediate steps in mineralocorticoid and glucocorticoid
biosynthesis (25).
The genes are scattered throughout the HLA region, the HLA class III region being
the most gene-rich region with approximately one gene per 15 kb (26). In addition
to functional genes, HLA contains numerous pseudogenes, repeated stretches
called microsatellites and genes without a yet identified functions.
Linkage disequilibrium and ancestral HLA haplotypes
Strong linkage disequilibrium is a special feature within the HLA region. It is a
phenomenon linking two alleles so that they occur together more frequently than
expected. For example the gene frequencies for both HLA-A*01 and HLA-B*08 are
about 16% in Finland (27). If their inheritance was random and independent of
each other the frequency of the combination of A1 and B8 would be about 2.5%
(16% x 16%) but in reality it is about 7.7% (28), meaning alleles occur more commonly
together than expected.
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A set of alleles, which are inherited en bloc, is called a haplotype. The conserved
allele combinations within HLA region are called extended or ancestral haplotypes
(AH). The ancestral haplotypes are relatively similar between populations and have
been claimed to cover even 30% of the known haplotypes in Caucasoids (29).
However their frequencies are population specific as a result of population history
and selection pressure.
One well known ancestral haplotype is HLA-A1;B8;DR3;DQ2 i.e. AH 8.1. The AH
8.1 is very common in Caucasoids with a frequency of 4,7% in Finns (28). It has
been shown to extend exceptionally long, even 6 Mb telomeric from HLA-A until
microsatellite D6S276 (30) and on centromeric side HLA-DPB*0101 is often part of
it (31). This is exceptional as DPB1 is rarely in linkage disequilibrium with other
class II genes. The AH 8.1 is well studied as many diseases associate to it and it
has special immunological character e.g. apoptosis impairment (32), lower cytokine
production and an increase of IgM producing B cells (31).
The reasons for the conservation of ancestral haplotypes are still unknown. There
has been speculation of the advantages of maintaining allelic combinations and
thus providing special phenotypes. The AHs may also lack some recombination-
promoting sequences, so called hotspots, preventing changes or they are simply
so new that there has not been enough time for changes to occur yet (31).
Crossovers cause interlocus recombinations and thus create new haplotypes.
Crossovers are restricted to certain places, hotspots. The hotspots split the genome
into relatively stable blocks with high linkage disequilibrium. The length of the blocks
in Caucasoids is quite constant, about 50-60 kb and the hotspot regions cover
circa 5 kb. However the length of blocks varies between population and e.g.
extending much less in Nigerians (33). This can be due to selection and population
history: size and amount of admixture. The length of blocks varies also between
chromosomal locations and in the HLA region some exceptionally conserved blocks
i.e. ancestral haplotypes can be seen.
The well known hotspots within the HLA class II region are located in four places:
between HLA-DOA and RING3 (really interesting new gene 3), between DQB3 and
DQB1 and around TAP2 (34;35) and in the vicinity of DMB (36). On the other hand
there is almost a total lack of recombinations between DQ and DR and DP and
DOA. In the class I region there are two hotspots namely around P5 and HLA-E,
maybe also between HLA-C and OTF3 (octamer-binding transcription factor 3)
and in centromeric of MICA (37) leaving at least one unbreakable region between
HLA-B and -C (38).
Hotspots were noticed to be partly haplotype specific in mouse (39) and later same
phenomenon was observed in humans with the rare HLA-B60;Cw*0304 haplotype
(40) and with the HLA-B47;DR7 haplotype (41) both having recombinations occurring
between the TNFa and D6S273 microsatellite marker.
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Class Class II other
B27 Ankylosing spondylitis DR4, DQ8, DQ2* Type 1 diabetes HFE Haemochromatosis
B53 Malaria DR2,DR3 SLE CYP21B CAH
B51 Bechet's syndrome DR4 Rheumatoid arthritis C4A SLE
A2902 Birdshot retinitis DR2, DQ6 Multiple sclerosis
Cw6 Psoriasis vulgaris DQ2*, DQ8 Coeliac disease
DQ6 Narcolepsy
Disease associations
Over 500 diseases are associated either with classical HLA alleles, with some other
genes within the HLA region or with whole HLA haplotypes. Many of them are
autoimmune disorders, multifactorial diseases with the HLA gene being only one of
numerous predisposing or protecting factors. (Table 2)
An example of a disease with a specific predisposing HLA allele is ankylosing
spondylitis which is associated with HLA-B*27 so strongly that HLA-B typing is
used even as a diagnostic tool; the B27 increases relative risk by 150 compared to
people not having that specific HLA-B allele. Alleles can also be protective like
HLA-B*53 is for malaria caused by infection of Plasmodium falciparum. People with
the B53, especially homozygous for the B53 resist malaria well or suffer mild
symptoms compared with non-B53 carriers. The B53 is relatively common in sub
Saharan people but rare in non-African populations. Defects in genes regulating
other than obvious immune function but still located in or near the HLA region may
cause iron-storage disease, haemochromatosis (HFE gene) or congenital adrenal
hyperplasia (CYP21B gene). (42;43)
The disease associations may be relatively complex e.g. in multiple sclerosis
and type I diabetes. Multiple sclerosis seems to have one strong predisposing
HLA DR;DQ haplotype as well as other minor, maybe population specific
protective and predisposing haplotypes (44). The most predisposing haplotype
combination associated with type 1 diabetes is DR4;DQ8/DR3;DQ2, where the
predisposing part is the combination of DQA1*03 (of DQ8 molecule) and
DQB1*02 (of DQ2 molecule). However both DQ8 and DQ2 molecules
themselves are also predisposing in a single dose. It is noted that in addition
to DQ molecules DR alleles also have an effect on the development of type 1
diabetes. Different DRB1*04 alleles have varying risk, DRB1*0405 and *0401
being the most predisposing followed by *0402. HLA-DRB1*0406 and *0403
are dominantly protective alleles besides DQ6 molecule. In addition to these class
II alleles, over 20 putative diabetes-predisposing loci have been reported, of which
class I alleles HLA-A*2401 and A*3002 are some of the latest. (45-48)
Table 2. Numerous diseases are associated with the HLA region, either with classical class I
or class II genes or with other loci.
*DQ2 is considered here as a combination of DQA1*05 and DQB1*02.
CAH = Congenital adrenal hyperplasia, SLE = Systemic lupus erythematosus
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GENETICS OF MULTIFACTORIAL (‘COMPLEX’) DISEASES
Complex diseases
For the development of a multifactorial disease a set of genes and certain
environmental factor(s) are needed (Fig. 5). The number of the susceptibility genes
may be large and even differ between individual patients. In addition to the locus
heterogeneity, the predisposing alleles at a specific locus may vary and the genes
interact with each other epistatically. Also incomplete penetrance, a non-uniform
occurrence of a disease between individuals with the same set of susceptibility
genes, or phenocopies, the same phenotype resulting from different set of genes,
are typical features of complex diseases. As the multifactorial disorders do not
follow the classical Mendelian laws, the onset of diseases may not be readily
predicted from the family history. (49)
The effect of the environment varies between diseases. Sometimes the environmental
factors, at least the major ones with direct effect, are known, like gluten in coeliac
disease or smoking in lung cancer. Increased incidence of asthma has been
explained by a lower burden of parasites causing the immune system to turn against
normally neutral antigens like pollen or even the body itself inflicting autoimmune
diseases. Bacterial DNA, viruses and parts of micro-organisms have also been
associated with the disease development; as adjuvants they may stimulate the
immune system into overactivation and hence induce autoimmune disease in
susceptible individuals.
Most autoimmune diseases are complex disorders with a strong HLA association.
They are chronic conditions caused by the breakage of immunologic tolerance to
self-antigens. Many of the autoimmune diseases are more common in females
Figure 5. Many factors influence the development of complex disease. There can be
numerous different genetic factors (1-4) in addition to environmental and cultural factors
(5). The combination of genetic factors may vary between people and genes themselves
may influence each other epistatically (6). The statistical methods rely on markers (7) that
can be used to locate predisposing genetic factors (8).
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than males and on average affect 3-5% of the general population. The diseases
can be classified as organ specific like type 1 diabetes where pancreatic islet cells
are destroyed or systemic ones which affect the whole body such as systemic
lupus erythematosus. (50)
Genetic studies
Attempts to solve the predisposing genes behind complex diseases have proven
to be a hard task as the genes with small effects vary between similarly affected
people. An essential assumption to overcome these obstacles is a carefully chosen
study material or methods. A difficulty is to get as many genetically homogenous
patients as possible, but still have a sufficiently large number of patients.
Choosing material
To diminish the effect of the environment or other genes, the chosen patients should
be as similar as possible for the genetic, environmental and cultural risk factors.
The genetic homogeneity is maximum when studying monozygous twins and they
are valuable samples for measuring the overall effect of genes versus the
environment by concordance. In an attempt to find predisposing genes the
monozygotic twins are useless. Instead dizygotic twins, siblings or relatively
homogenous populations have been widely used as too much heterogenity exists
in most general population samples. After the gene has been roughly located the
transracial studies may be helpful in pinpointing the exact predisposing factor.
Twins
In classical twin studies the concordance and discordance rates of monozygotic and
dizygotic twin pairs are compared to define the relative effects of genes and
environmental factors for the outbreak of a disease. This clearly is one of the first
points in any study of the genetics of a disease. Casewise concordance rates for
typical complex diseases are variable: they vary between 25-86 % for monozygotic
twins and are significantly lower (0-20 %) for dizygotic twins (Table 3)(51-53). When
the concordance rate in monozygotic twins is high, as is the case in late onset diabetes
(54) or coeliac disease the genes can be assumed to play a more important role than
the environmental factors. If there is no difference in concordance rates between
monozygotic and dizygotic twins, the role of genes must be assumed to be low and
the effect of a shared environment high. Usually diseases occurring in older people
have a higher concordance compared with ones affecting children (55).
It is important to remember that not even monozygotic twins are ever genetically
totally identical, a percent difference is allowed. This difference comes from point
mutations, skewed X- chromosomal inactivation, non-disjunctions and from gene
rearrangements of Ig and T cell reseptors. In addition to the genetic differences,
there may be differences in methylation and in the levels of protein translation.
Monozygotic twins also commonly share a similar childhood environment, and
pressure from the surroundings may link the twins more closely together than other
siblings adding to the shared environmental factors. (56)
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MZ DZ REFERENCES
Coeliac disease 86 20 Greco et al  2002
Crohn’s disease 33 12 Thompson et al  1996 
Graves disease 36 0 Cooper et al  1999
Multiple sclerosis 34 6 Cooper et al  1999
Rheumatoid arthritis 25 7 Cooper et al  1999
Systemic lupus erythematosus 36 3 Cooper et al  1999
Type 1 diabetes 46 13 Cooper et al  1999
Ulcerative colitis 27 6 Thompson et al  1996 
Population isolates
An attempt to decrease patients heterogenity and reduce the complexity of polygenic
disorders has brought population isolates into science (57). People from isolates
have less environmental and genotype variation, the latter meaning less allelic and
locus heterogeneity and longer conserved haplotypes caused by linkage
disequilibrium. Hence less markers and fewer families are needed to study compared
to analysis with outbred populations. Isolated populations also have relatively more
recessive disorders and a usually well documented history with known pedigrees.
These reasons have made isolates the most important tool in genetic studies of
inherited disorders. The drawbacks compared to mixed populations include a limited
number of patients and occasionally negative attitudes towards participating in
studies.
The Finnish population has been used widely in the search for genes for genetic
disorders. Finns have a typical founder effect caused by a few ancient invaders
who settled in with a limited number of genotypes. Throughout the thousands of
years with relatively few immigrants, some bottlenecks and times of rapid growth,
genetic drift has had time to modify the gene pool seen in Finnish people
today. A typical character is the Finnish disease heritage with about 40 diseases
observed with a higher frequency in Finland than elsewhere in the world and
commonly caused by a major ‘Finnish’ gene mutation. On the other hand, the
population has much less certain relatively common inherited diseases such as
cystic fibrosis and phenylketonuria. The Finnish population is also favoured in studies
because of high quality public healthcare and church records dating from the 17th
century. All this enables collections of large pedigrees with accurate and well
preserved medical records. (58;59)
Other populations actively applied in genetic mapping studies include small isolated
groups of Amish, Hutterites and Mennonites from the USA, genetically peculiar
Basques from the Basque Country, Bedouins from the Middle East and North Africa
with a family study of nonsyndronic deafness, well studied Icelanders with the
on-going deCODE project, Sardinians from their isolated island and Jews, especially
Ashkenazi Jews. In the need for even smaller subisolates and more homogeneous
Table 3. Concordance rates of monozygotic (MZ) and dizygotic (DZ) twins for various
autoimmune diseases are low compared with concordance in coeliac disease.
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people with wide genealogical databases, people from Quebec, Costa Rica, parts
of Holland and Finland have been studied. (59;60)
Phenotypes
If the disease is rare it might be impossible to collect a sufficient number of patients
from any population isolate. Then one can try to limit the genetic heterogeneity by
choosing patients with only certain strictly restricted phenotypes as it can be thought
that more similar phenotypes would rise from a more similar set of genetic factors.
By dividing migraine patients according to their phenotypes, two different
predisposing loci for the different subtypes have thus far been found (61;62).
It is important to define all patient data accurately from the beginning to allow later
grouping of patients based on e.g. age of onset, manifestation type or degree of
difficulty, sex or inheritance. Still the results may be unreliable as there might be
phenocopies resulting in similar phenotypes from different sets of genes or a specific
mutation may not cause the same symptoms. This is typical for the CYP21B gene
deficiency as the siblings carrying the same mutations may have variable phenotypes
ranging from totally symptomless to severely affected ones (63).
Choosing methods
Statistical methods are based on measuring the correlation between the disease
phenotype and genotype. The basic methods used for defining the predisposing
genetic loci by correlation are linkage and association methods.
Microsatellite markers and defining genotypes
The genotypes can be defined by genetic markers, classically by blood grouping,
later with restriction fragment analysis (RFLP), short tandem repeats or by single-
nucleotide polymorphisms, SNPs. SNPs are especially suited for analysis where
dense marker maps are needed such as in candidate gene studies as there is
about one SNP every 1.9 kb (64).
Microsatellites are short tandem repeats, ranging from 2-6 nucleotides, the most
common being (CA)n repeat. Sequences can be repeated from tens to hundreds of
times. Microsatellites are widely used in genotyping as they are common, found
approximately one in every 10 kb, and throughout the genome (65). These markers
are informative if they have more than five alleles and a heterozygosity value
exceeding 0,75. On average markers in the HLA region have 8,5 alleles and more
than half have a heterozygosity value over 75% (66).
Microsatellite marker genotyping is relatively easy with automated electrophoresis.
The microsatellite allele frequencies are population specific. The different alleles
are produced by either unequal crossing over or slippage during DNA replication.
Usually the number of repeats changes by one, either increasing or decreasing,
and more commonly changing in already long sequences (67;68). The role of
microsatellites, if any, is unknown but they are assumed to condense DNA packing,
22 REVIEW OF THE LITERATURE
regulate gene activation or to act as recombination hotspots (69). The increase in
the number of repeats is known to affect the probability of developing a fragile X
syndrome (70).
Linkage studies
Parametric linkage has been used successfully when mapping genes causing simple
Mendelian diseases (71). It is a powerful and practical method when large families
with at least two affected individuals are available and certain genetic parameters,
such as penetrance, dominance/recessiviness, recombination fractions, trait and
marker allele frequencies can be accurately measured. As these parameters are
seldom known, or may not actually ever be defined for complex diseases, the
method is not very effective in multifactorial diseases.
Linkage study is based on the assumption that affected family members share the
same predisposing gene. As the patients with the shared predisposing gene seldom
have recombinations in the vicinity of the disease gene, with linkage studies the
predisposing gene is tried to be found with the help of markers located next to the
disease gene. This conserved region is assumed to have less recombinations
indicated by the theta value, q  < 0.5. The linkage results are plotted to a logarithm
of odds (LOD, a lod score). A lod score larger than 3 is considered significant for a
single tested locus and a LOD >3.3 for genome-wide analysis (72).
In non-parametric methods the penetrance is not defined, but the allele sharing of
relatives with a similar phenotype is measured. This can be done within families
with parents and two affected siblings (affected sib-pair method) or between other
relatives with the help of inheritance vectors (non-parametric linkage analysis). Both
methods have numerous variations.
In genome-wide scans predisposing genes are tried to be found by using evenly
spaced genetic markers covering the whole genome. Following the initial genome
screen, so called candidate regions with the highest lod scores are narrowed down
with other methods. Genome wide scans are usually performed with non-parametric
sib pair methods in a particular population and they need to be replicated in other
populations, even in old outbreed populations (73).
Association studies
The idea of association studies is to find alleles which are inherited by patients
more commonly than by controls. The shared region indicated by shared alleles
can be expected to contain the predisposing factor for the disease.
The case-control approach compares the allele frequencies of unrelated patients
and their matched controls. Of the family-based tests the simplest method is the
transmission/disequilibrium test, TDT, where inheritance from heterozygous parents
is traced to affected offspring and the number of transmissions and non-
transmissions are plotted in a contingency table (74). The advantage of a family-
based TDT is the lack of a population stratification error but on the other hand,
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collecting families is time-consuming and not always possible. Nowadays there are
a wide variety of association tests either based on the case-control or family studies.
Tests based on association are used to narrow down the candidate regions revealed
by linkage studies or when the functional candidate gene approach is used. Then
numerous markers are genotyped densely covering a small precise region. The
result will pinpoint the specific region with the highest linkage disequilibrium between
the disease locus and its nearest marker. Unfortunately the use of dense marker
maps increases type I error. Hence it is important to have unaffected well matched
controls showing that the linkage disequilibrium is due to the proximity to the disease
locus and not because it is common in the general population (75).
COELIAC DISEASE, GLUTEN SENSITIVE ENTEROPATHY
Coeliac disease (CD) (OMIM 142800) is a multifactorial enteropathy, where the main
environmental risk factor is gluten. Gluten is a storage protein in cereals and the
ingestion of this protein from wheat, barley or rye may cause mucosal lesions in the
small bowel in genetically susceptible individuals. Mucosal injury usually affects the
patients’ quality of life, and in the long run increases the risk for associated diseases.
Aretaeus from Cappadocia was the first to describe a gastrointestinal condition
resembling coeliac disease already in the second century A.D., but the first thorough
description of clinical symptoms by doctor Gee dates back to the year 1888. It took
another 60 years and World War II before the role of gluten as the trigger for coeliac
symptoms was solved. Dutch paediatrician Dicke noticed a recovery of coeliac
patients during a shortage of bread in the war time and the reoccurrence of
symptoms after cereals were reintroduced to diet (76). Since then the only permanent
treatment for patients has been a strict gluten free diet. (77)
Clinical picture
Classical coeliac disease is an enteropathy where gluten ingestion destroys the
architecture of the small intestine causing a variety of symptoms. In children the
symptoms follow the introduction of cereals into diet. The classical gastrointestinal
symptoms in paediatric patients are chronic diarrhoea or steatorrhoea, vomiting,
abdominal distension and pain, oedema and pallor. Adult patients may present
episodic diarrhoea, weight loss, abdominal discomfort, bloating and flatulence.
Today most of the diagnosed patients only have mild symptoms.
The various complications have been shown to be very common in coeliac disease.
In paediatric patients untreated CD gives rise to e.g. impaired growth, pubertial
delay, anaemia with different mineral deficiencies, defects in dental enamel and
behavioural disturbances. Many adults have iron-deficiency or other anaemia, lactose
intolerance, osteoporosis, bleeding disturbances or aphthous ulcerations. These
patients may totally lack classical gastrointestinal symptoms.
Coeliac disease has special risk groups: the first degree relatives of CD patients
and individuals with certain physical conditions or diseases. Diseases which are
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overrepresented in CD patients or where CD is overrepresented (Table 4) include
many HLA-DR3 or -DQ2 associated autoimmune and gastrointestinal disorders as
well as problems affecting the nervous system, bones, or reproduction (78-80).
Often patients with associated conditions have a symptomless, so called silent
form of CD, which is only found in screenings.
The magnitude of screening studies is shown by a large Italian paediatric study
which reported that for every diagnosed patient with CD symptoms as many as
seven new patients with a silent form can be found (81). Only on a continuous
gluten free diet the symptoms of other complications might ease or disappear
improving the quality of life (82), the risk for additional disorders such as malignancy
or severe liver diseases return to the level of healthy people (83;84) and child patients
may catch-up growth (85). The older the person is and hence the longer the time of
gluten exposure at the time of diagnosis, the more possibilities he has for the
outbreak of additional autoimmune disorders (86).
As screening studies have revealed an enormous number of people with only mild
symptoms or a totally symptomless disease the picture of CD has had to shift from
classical coeliac enteropathy to an autoimmune syndrome with different
manifestations seen in any part of body. However, CD cannot be considered
unambiguously as a classical autoimmune disease, as the symptoms and
autoantibodies disappear after gluten removal.
Table 4. Coeliac patients have a diverse repertoire of symptoms and conditions and in
addition they may have various autoimmune disorders more commonly than the general
population.
Symptoms and conditions Autoimmune disorders
Abdominal distention Addison's disease
Abdominal pain Alopecia areata
Arthralgia Autoimmune thyroiditis
Ataxia Juvenil chronic arthritis
Borborygmia Primary biliary cirrhosis
Dental enamel defects Selective IgA deficiency
Diarrhea Sjögren's syndrome
Down syndrome Type 1 diabetes
Epilepsy
IgA glomerulonephritis
Loose stool
Miscarriages and infertitily
Osteopenia
Osteoporosis
Peripherial neuropathy
Small bowel lymphoma or cancer
Steatorrhea
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Diagnosis
For the diagnosis of coeliac disease, it is mandatory to take a small intestinal
biopsy. Changes of mucosa lesions are classified into five categories (Fig. 6)
according to the stages of villus atrophy, hyperplasia of crypt cells and the
occurrence of intraepithelial lymphocytes (87). For the CD diagnosis no less
than stage 3 lesion is required. In the past it was the custom to take three
biopsies to ensure CD diagnosis: one before treatment, the second during a
gluten free diet and the third after a challenge with gluten. The mucosa of the
intestine should have shown signs of abnormality in the first and last biopsy.
Now, repeated biopsies with gluten challenge are only used with children
diagnosed under the age of two or if there are any doubts about the initial
diagnosis (88).
In addition to the clinical picture and mucosal lesions detectable in biopsies, patients
have specific antibodies well-suited for diagnostics. According to the latest revised
ESPGAN (European Society for Paediatric Gastroenterology and Nutrition) criteria
‘the finding of circulating antibodies at time of diagnosis and their disappearance
when the patient is taking a gluten free diet add weight to the diagnosis’ (88).
These antibody tests were first based on serum antigliadin and antireticulin
antibodies, but now more sensitive and specific antiendomysial and tissue-
transglutaminase antibody tests are displacing them (89-92).
Prevalence
Susceptibility to coeliac disease may be pictured as an iceberg (Fig. 7). The
iceberg consists of people with a basic genetic susceptibility for CD, but of
whom the majority will never be affected. Some people, so called latent cases,
have coeliac antibody pattern and an increased number of intraepithelial g d  T
cells but no signs of overt mucosal lesions (93). Patients with the silent form
are also symptomless but already have coeliac manifestation in the intestine
as well as detectable antibodies. The small visible part of the iceberg consists
of patients with clinical CD (94).
Figure 6. Spectrum of consecutive mucosal stages seen in gluten sensitivity according to
Marsh, 1992: type 0 also called pre-infiltrative is the pattern of healthy mucosa but it may
already present anti-gliadin antibodies, type 1 has infiltration of intraepithelial lymphocytes,
type 2 in addition to intraepithelial lymphocytes also crypt hypertrophy, type 3 flat destructive
with hypertrophic crypts, lamina propria swelling and a flattened surface epithelium and
type 4 is a totally atrophic mucosa with possibilities of lymphomas.
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The technical and economical possibilities to screen risk groups or sub populations
with antibody tests as well as the wider knowledge of the symptoms among clinicians
has revealed more of the coeliac iceberg. Previously coeliac disease was estimated
to affect 1:1000 Caucasian based on the number of people with clinical
manifestations, but now the screening studies have obtained prevalences between
1:300 to 1:100 (95-97). So far the highest population prevalence reported has come
from Algeria where the frequency of the antiendomysial antibody was detected in
5.6% of Saharawi children (98). Prevalences of this world-wide disorder however
vary between populations due to differences e.g. in dietary patterns, infant feeding
habits and susceptibility gene frequencies.
Dermatitis herpetiformis
One of the diseases which is strongly linked to CD is dermatitis herpetiformis (DH),
previously called Durhing’s disease (99-101). In Finland it is already accepted that
DH is only one manifestation type of gluten sensitivity and hence patients with DH
can be considered as coeliac patients. In this thesis too, the entity for CD covers
both the intestinal as well as dermatological manifestation type, the classical CD
(cCD) refers only to the intestinal form.
Figure 7. The coeliac iceberg consists of people with predisposing genetics for CD.
Individuals with latent CD also have coeliac antibody repertoire, silent patients already
detectable mucosal manifestation. The symptomatic patients are only the minority, the visible
part, of the iceberg. CD = coeliac disease
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DH is classified as a dermatological disorder where patients have itchy blisters
located symmetrically in the skin of elbows, knees and buttocks, sometimes also in
the scalp and face. 10% of the patients complain about intestinal problems similar
to classical CD patients. In microscopical examinations granular IgA deposits seen
in healthy papillary dermis are the hallmark of DH, but all patients also have cCD
antibody repertoire, an increased number of intraepithelial lymphocytes in intestinal
mucosa, and 75% have mucosal changes revealed by an intestinal biopsy (102;103).
In addition to similar symptoms, antibodies and mucosal morphology seen in DH
and cCD there is also the same, and the only, permanent treatment, gluten free
diet, for both manifestations. Adherence to the diet alleviates the skin and intestinal
symptoms and also lowers risk for the outburst of other associated complications
in DH patients (104-106). Similar genetic factors also influence the onset of the two
manifestations of gluten sensitivity. Nearly every fifth of first degree relatives has
either the skin or intestinal form of gluten sensitivity independently of the
manifestation type of the family’s proband (107). Classical CD and DH have also
high, over 80% incidence among monozygotic twins and the twins may even be
discordant for the type of symptoms caused by gluten sensitivity (53;108-111).
Despite many similarities there are also notable differences. DH is a rarer disorder
with a prevalence of 1:1500 compared with intestinal CD which is about ten times
more common in Finland (112). The distributions of sex and the age of onset are
also different as the intestinal manifestation is seen predominantly in females of all
age groups, whereas DH occurs typically in men of the age 30-40 (106). The
symptoms on the skin react more slowly to gluten withdrawal than intestinal mucosa;
it can take weeks to months after starting a gluten free diet before DH patients may
decrease the drug intake for irritating skin symptoms. On gluten challenge the
dermatological symptoms appear after approximately 1,5 months and IgA deposits
on the skin stay visible for a long time; they can be detected as long as 13 years
after starting the proper diet (113;114). For patients with only intestinal symptoms
the intestinal mucosa heals completely within a couple of years (115). If recovery
takes a longer time it can be considered as refractory coeliac sprue with a poor
prognosis (116).
Pathogenesis
The pathogenic mechanisms causing coeliac disease have been unveiled slowly
and are still in many parts unsolved. However CD could be thought to be a
comparatively easy disorder to study as the main environmental risk factor, gluten,
is known, particular HLA-DQ genes are shown to play an important role, there is no
lack of patients with confirmed diagnosis and the affected organ is relatively easy
to study even in vitro.
The reaction cascade in the small intestine of a patient starts as gluten peptides
transpass the intestinal epithelia of villus and enters the lamina propria. There gluten
antigens are recognised and caught by antigen presenting cells. As the CD specific
antigen presenting HLA molecules, DQ2 and DQ8, preferentially bind peptides
with negatively charged amino acids, the positive glutamine residues of gluten
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antigens are deaminated to glutamic acid. This deamination is catalysed by an
enzyme tissue transglutaminase (tTG) (117;118). Tissue transglutaminase can also
cross-link gluten residues to itself to produce antigen-tTG-complexes (119).
The antigen is presented to CD4+ T cells which after activation start to differentiate
and proliferate into Th1 and Th2 types (Fig. 8). Th1 cells producing IFNg  and TNF a
activate cell-mediated immune regulation and cytokine cascade causing epithelial
proliferation and crypt cell hyperplasia (120). Th2 cells responsible for humoral
response activate B cells to produce antibodies towards tTG and gluten. The
blockage of tTG by autoantibodies can have a broad effect related to epithelial
destruction and lesion formation. (121-123)
The result is a mass of apoptotic epithelial cells, the destruction of the intestinal
villus and crypt cells proliferation typically seen in small bowel biopsies of coeliac
patients (see Fig. 6). As the permeability of mucosal lesions is increased, gluten
antigens may freely enter and cause more damage. Lesions also have an abnormal
number of gd  intraepithelial lymphocytes which still have an unknown role, but may
take part in lesion formation.
Patients with a dermatological manifestation of coeliac disease, dermatitis
herpetiformis, also have tissue transglutaminase as an autoantigen but in addition
Figure 8. Gluten intake triggers the pathogenesis in coeliac patients. Antigen presenting
cells (APC) present gluten peptides and gluten-transglutaminase derived peptides in their
HLA molecules to T cell receptors. This induces T cell development either to Th1 type, cell-
mediated immunoregulation with activated cytotoxic T lymphocytes (CTL) and production
of various cytokines, or Th2 type, triggering B cells to produce antibodies to gluten and
transglutaminase. Antibodies, cytokines and cytotoxic T cells cause villus atrophy,
hyperplasia of crypt cells and intestinal lesion formation.
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antibodies against epidermal transglutaminase (eTG)(124). This autoantigen
catalysing posttranslational modifications shows conservation in enzymatically
relevant domains with tTG and the same antibodies can cross-react with them.
Sardy et al (2002)(124) hypothesised that DH patients first develop silent CD as a
result of low-affinity anti-tTG antibodies, but the continuing gluten provocation would
raise cross-reactive antibodies against eTG, too. Antibody-eTG complexes could
later provoke the visible dermatological symptoms.
Genetics
Coeliac disease has a clear genetic component and there is currently increasing
evidence that it can be regarded as a multifactorial disease where both environmental
and various genetic factors determine the overall susceptibility. The genetic
predisposition has been obvious although until to recently no systematic and
thorough twin studies had been published; the earlier studies suggested a
concordance of 50-80% (125). Also, the prevalences of 10-20% for first degree
relatives of probands have been reported in various family studies (107;126;127).
The relative risk for siblings ( l s) to become affected is about 30 (128) compared to
the general population. Finally, also speaking for the genetic component is the fact
that CD shows strong association with certain HLA alleles.
HLA class II DQ2 and DQ8
Already thirty years ago CD was noted to be associated with the HLA region, first
with class I alleles, HLA-A1 and -B8 (129;130). Later when HLA typing techniques
advanced it was observed that the primary association might be with HLA class II
alleles DR3 (131;132), DR5 and DR7 (133;134), and finally with DQ2 alleles (135).
The association of HLA-DQ2 heterodimer with CD, which is now believed to be
genuine, was reported about fifteen years ago (136).
Tosi et al (1983)(135) using serological data and finally Sollid et al (1989)(136)
using DNA techniques, established that a particular HLA-DQ2 heterodimer confers
primary risk to CD (Fig. 9). This DQ2 heterodimer is encoded by the DQA1*05 and
DQB1*02 alleles. It is often called DQ2 but it should be noted that DQ2 refers to
any polymorphic allele combination equivalent to serological DQ2 specificity and
this nomenclature may cause confusion. These DQA1*05 and DQB1*02 alleles
can be located either in a single haplotype, in cis, with DRB1*03 (DR3) or in different
haplotypes, in trans, with DRB1*11 or *12  (DR5), occasionally also with DRB1*13
(DR6), and DRB1*07 (DR7). In Northern Europe, about 90% of coeliac patients
carry the DR3;DQ2 haplotype, but in southern Europe, the trans combination, i.e.
DR5(DR6)/DR7 heterozygotes, is more commonly present in patients, most probably
as a result of different frequencies of the haplotypes in the general populations
(133;137-140). The DQ2 heterodimers in DR3 and DR5(DR6)/DR7 cases are not
totally identical, however (Fig. 9); with DR3 the heterodimer is encoded by the
DQA1*0501 and DQB1*0201 alleles, but in trans by DQA1*0505 and DQB1*0202
alleles. The differences in DQa  chains by one residue in the leader peptide and in
DQb  chains by one amino acid residue in the membrane proximal domain (141)
are assumed to be of no functional significance.
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Determination of HLA-B alleles in CD patients have revealed that the haplotypes in
coeliac patients are often the well known ancestral haplotypes B8;DR3;DQ2 or
B18;DR3;DQ2, where the only common region is the DR3;DQ2 part (142;143).
While sequencing DQA1*05 and DQB1*02 alleles of CD patients (144) and DH
patients no (145) particular ‘CD-mutations’ were detected. Also DQ2 segregation
studies within families revealed no skewing (146). As a conclusion there is relatively
strong genetic evidence that the frequent HLA-DQ2 is the major predisposing factor
for CD.
Further evidence for the primary role of DQ2 has come from functional studies.
T cells, which are specific for gliadin (soluble part of gluten of wheat), were isolated
from the intestinal mucosa of CD patients. They were restricted by HLA-DQ2, that
is, they were activated if the antigen was presented by DQ2 molecules encoded by
DQA1*05 and DQB1*02 alleles (147).
As the common DQ2 molecule seen in about every fifth Caucasoid proved to be
the major risk factor, its dose effect has also been studied. It seems that a higher
number of patients are heterozygous for DR3;DQ2/DR7;DQ2 (148) or homozygous
for DR3;DQ2 (140) than expected from the general population frequencies. Thus a
double dose of the DQB1*02 allele may increase the relative risk for the onset and
influence the manifestation type of disease or the age of onset (149-152). Recently
Vader et al (2002) (153) published that also the DQ2 molecule encoded by DQA1*02
and DQB1*02 alleles can present gluten antigens partly explaining the over-
representation of DR3;DQ2/DR7;DQ2 patients.
The HLA association in HLA-DQ2 negative patients has been a matter of some
debate recently. Patients negative for HLA-DQ2 usually seem to carry the DR4;DQ8
haplotype encoded by DRB1*04; DQA1*0301; DQB1*0302. The frequency of
DR4;DQ8 positive patients represents only a minor part (5-12%) of patients (154;155)
Figure 9. The predisposing molecules for coeliac disease are DQ2 and DQ8. The DQ2
molecule is encoded by DQA1*05 and DQB1*02 differing at specific alleles depending on
whether the molecule is encoded in cis or in trans.  The DQ8 molecule is always encoded
by DQA1*0301 and DQB1*0302. The encoding alleles are located in DRB1;DQA1;DQB1
haplotypes which are often abbreviated with serological names of molecules.
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with an interesting exception of Chilean patients who have a higher frequency of
DQ8 than DQ2 (156), again possibly reflecting the general population frequencies.
The actual susceptibility gene in DQ2 negatives has been under debate with
possibilities of the DQ8 molecule, different DRB1*04 alleles or the DRB4 gene,
which is expressed only in DRB1*04, DRB1*07 and DRB1*09 positive haplotypes.
A major claim has been that if the predisposing locus was the DRB4 gene, it would
explain the association with DR4;DQ8 haplotypes as well as the high risk effect of
DR3;DQ2/DR7;DQ2 combination. In addition, the DRB4 molecule (DR53) has also
been showed to bind gliadin-derived peptides (157), possibly explaining some earlier
reports of gliadin-specific T cells observed to be restricted by DR7 and DR53 (158)
haplotypes which carry the DRB4 gene. Speaking strongly against the role of DRB4
are the facts that there is no excess of DR4;DQ7 or DR9;DQ9 haplotypes in CD
patients, nor a different distribution of DRB4 alleles between patients and controls
(159) and not all DQ2 negative patients have the DRB4 gene (160).
There is no systematic data of the effect of different DRB1*04 alleles in CD
susceptibility. Different DRB1*04 alleles are known to be either predisposing or
protective to type 1 diabetes (42) and hence, they may modify the effect of primary
DQ association in this disease. However the most realistic option for the predisposing
role is left to DQ8 as it can bind gliadin (161;162).
Search for other genes
Both HLA-DQ2 and -DQ8 are common in all European populations with a combined
frequency of 20-30% (163;164). It has been estimated that the HLA locus contributes
40% at most of the familial risk to CD (128;165). Also a moderate concordance of
30-50% in HLA identical siblings (166) and a probandwise concordance of 20% in
dizygotic twins (53) suggest the existence of other predisposing genetic factors.
Genome wide scans with nuclear families or sib pairs have revealed numerous
chromosomal regions possibly predisposing to coeliac disease (167-173), but follow
up studies have seldom confirmed the original results (174;175). The only
indisputable region is still HLA, whereas the others may be either minor, population
specific loci or false positive results. All are common problems in genetic analyses
in multifactorial diseases. Studies focusing on genes selected by proven or assumed
functional evidence have had similar difficulties; different results in different
populations are reality. The HLA region contains numerous interesting
immunorelated genes, but their association with or linkage to coeliac disease has
usually been attributed to linkage disequilibrium within the region or the results
have not been replicated in other studies (see Results and Discussion, pages 45-
46). Candidate genes outside of the HLA region now considered as the most
promising ones are a cluster on chromosome 2q33, including genes for the T cell
costimulatory molecules CTLA4 (cytotoxic T lymphocyte-associated 4), CD28 (176-
178), and ICOS (inducible co-stimulator) (179). No indication of linkage or association
has been found for other interesting candidate genes, such as T-cell receptors
(180), tissue transglutaminase genes (181), B7 genes which encode ligands for
CD28 and CTLA4 (182), or the IL12B gene, modifying expression of IL-12 (183).
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The IL12B gene is located in the region 5q31-33, which is considered one of the
most interesting regions detected from genome scans. The 5q31-33 region includes
a cytokine gene cluster for IL-3, -4, -5, -9 and IL-13. Another interesting region,
11q22 towards telomere, harbours the IL-10 receptor gene, genes encoding three
CD3 complex chains and genes for matrix metalloproteinase-1 and -3, but at least
matrix metalloproteinase-1 and -3 promoters are not shown to associate with coeliac
disease (184).
As the population specific linkage studies have very conflicting results, new methods
are developed to combine the data already available. In meta analysis the results
of genome scans are pooled together whereas in mega analysis the results are
divided into chromosomal regions and these are ranked in ascending order before
analysing the combined data. With a huge amount of information the effect of
population specificities and typing errors are reduced and the results can be
considered more accurate than in individual genome scans. The first combined
studies have already been accepted by European Journal of Human Immunology
(Meta-analysis by Babron M-C, Clerget-Darpoux R, Nilsson S, Ascher H, Ciclitira PJ,
Sollid LM, Partanen J, Greco L and the European Genetics Cluster on Coeliac
Disease; Mega-analysis by Nilsson S, Adamovic S, Naluai ÅT, Babron M-C,
Wahlström J,  Ascher H, Ciclitira PJ, Clerget-Darpoux R, Sollid LM, Partanen J,
Greco L and the European Genetics Cluster on Coeliac Disease).
Finnish studies on coeliac disease
Coeliac disease has been intensively studied in Finland and the first doctoral thesis
about ‘Duodeno-jejunal histology in the malabsorbtion syndrome in infants’ was
already published in the year 1966 by Pekka Kuitunen (185). Since then there has
been 31 thesis from Helsinki, Tampere, Turku, Oulu and Kuopio Universities (Table 5).
The subjects of these thesis have covered various aspects of coeliac research;
epidemiology widening the disease spectrum from strictly classical coeliac disease
to silent and latent manifestations and to dermatological form, pathogenesis from
cell cultures or biopsy studies to different antibodies, subsets of T cells and
adenovirus infections and genetics with research on HLA and HLA-unlinked genes.
Also CD associated disorders or manifestations seen e.g. in teeth, have been topics
of research as well as nutritional aspects of coeliac patients.
Table 5. Doctoral thesis about coeliac disease published in Finland since 1966.
Author (year) Title of thesis
 Pekka Kuitunen (1966) Duodeno-jejunal histology in the malabsorption syndrome in infants
 Pirkko Immonen (1968) Levels of the serum immunoglobulins g A, g G and g M  in the
 malabsorption syndrome in children
 Erkki Savilahti (1973) Suoliston immunoglobuliinit lapsuusiässä
 Timo Reunala (1977) Dermatits herpetiformis; genetic aspects and gluten-free diet treatment
 Matti Vuoristo (1979) Cholesterol metabolism in adult coeliac disease
 Jorma Kokkonen (1980) Lasten mahalaukun toiminnalliset häiriöt; tutkimus ohutsuoliperäistä
 malabsorbtiota, atopiaa, diabetesta ja Sjögrenin syndroomaa 
 sairastavien lasten mahalaukun erityistoiminnasta ja morfologiasta
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 Mikko Perkkiö (1981) Suoliston immunoglobuliinien kehitys ja muutokset ruoka-aine-
 sopimattomuustiloissa: suolibiopsioiden morfometrinen ja immunohisto-
 kemiallinen valo- ja elektromikroskopiatutkimus
 Matti Verkasalo (1982) Tissue antigents and clinical risk factors in intestinal cow's milk allergy
 and coeliac disease in children 
 Aira Laihinen (1986) Kutina ja raapiminen ihosairauksien kroonistajina: 
 psykosomaattinen tutkimus
 Eeva Vainio (1986) Antigliadin antibodies in dermatitis herpetiformis and gluten-sensitive 
 enteropathy
 Liisa Aine (1986) Dental enamel defects and dental maturity in children and adolescents
 with coeliac disease
 Olavi Hällström (1989) IgA-class reticulin antibody test in coeliac disease and dermatitis 
 herpetiformis
 Timo Klemola (1989) Immunoglobuliini A:n puutos lapsipotilailla
 Kati Holm (1993) Latent and silent coeliac disease
 Marja-Leena Lähdeaho (1994) Homology between adenovirus E1B protein and A-gliadin. 
 Adenovirus and A-gliadin specific B cell responses in coeliac disease
 Pekka Collin (1994) Associated diseases and survival in coeliac disease
 Mikael Kuitunen (1995) Intestinal permability to human a -lactalbumin, bovine b -
 lactoglobulin, mannitol and lactulose in healthy infants and 
 coeliac disease patients
 Tero Saukkonen (1996) Immune response to dietary proteins in children with insulin-dependent 
 diabetes mellitus
 Kristiina Airola (1997) Matrix metalloproteinases in human skin: expression of interstitial  
 collagenase, stromelysin-1, collagenase-3, and their tissue inhibitors 
 by keratinocytes
 Tarja Kemppainen (1997) Oat meal as a component of a gluten-free diet, nutrient intakes, 
 nutritional status and osteopenia in coeliac patients
 Anne Polvi (1998) Genetic suspectibility to coeliac disease: marjor histocompatibility 
 complex genes in coeliac disease and in its animal model
 Hannu Lähteenoja (1999) Coeliac disease and oral mucosa  
 Sari Iltanen (1999) Markers of coeliac disease latency
 Tuija Kerttula (1999) Circulating T-cell subsets in coeliac and HLA DQ2-positive individuals
 Tuula Sontag-Strohm (1999) Gluten protein composition and quality in bread wheats
 Katri Kaukinen (2000) Small bowel mucosa in suspected and confirmed coeliac disease 
 Satu Sulkanen (2000) Serum antibodies in coeliac disease
 Tomi Leivo (2000) Basement membrane zone proteins, epithelial integrins and TGF- b 
 system in reepithelialization, dermatitis herpetiformis and psoriasis; 
 modulation by isotretinoin, betamethasone and calcipotriol  
 Päivi Holopainen (2002) Genetic susceptibility to coeliac disease: HLA-unlinked candidate genes
 Timo Örmälä (2002) Age related changes in the immunology of the intestinal mucosa
 Tuula Halttunen (2002) Biological functions of coeliac disease antibodies
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AIMS OF THE STUDIES
The purpose of this thesis has been
to scrutinise the effect of the HLA gene region on gluten sensitivity, in particular to
search novel susceptibility genes in addition to the known HLA-DQ alleles; and
to evaluate the role of the HLA gene region in the different clinical manifestations of
gluten sensitivity.
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COELIAC DISEASE PATIENTS
Multiplex families (I,III,IV,V)
Samples from Finnish families with at least two siblings with gluten sensitivity have
been collected through advertising in the Finnish Coeliac Society’s newsletter. The
collection and the further screening procedures within the families have been
described by Mustalahti et al (2002)(186). Briefly, the diagnoses were confirmed by
scrutinising hospital records and all voluntary family members were screened for
the diagnostic anti-gliadin and anti-endomysial antibodies. A small bowel biopsy
was performed after a positive antibody test result. Altogether, 137 families (872
individuals) were collected and their samples were prepared for analysis. Of the
137 families, 110 had at least two affected siblings and they were the principal
study set of the present studies.
Every patient has given informed consent and the study has been accepted by the
Ethical Committee of Tampere University Hospital with permission number 95173.
In study I, 52 families with microsatellite markers typed on chromosome 5q31 were
included. In study III, one sib pair of each 110 families were studied. In study IV,
nine families with HLA-DQ2 homozygous parents were included. In study V, one
hundred families were screened for DQ2 negativity. These 100 families were those
included in the EU Consortium studies.
Simplex families (IV)
An earlier collection of Finnish CD family material consisted of 31 families (131
individuals) with at least one gluten sensitive patient (187). Five families overlapped
with the multiplex family material described above (186). All diagnosis were based
on ESPGAN criteria (88).
Four families with HLA-DQ2 homozygous parents were included in study IV. The
approval to study coeliac disease in these families came from the Ethical Committee
of the Tampere University Hospital.
Monozygotic twin pairs (II)
From a total of 1292 dermatitis herpetiformis patients identified during 1969 – 1999
in Finnish dermatological clinics, 6 patients were reported to have a monozygotic
twin. The diagnosis of DH were based on the presence of a granular IgA deposit in
the skin, and cCD on the demonstration of subtotal or partial villous atrophy in the
small intestine and histological response on the gluten free diet treatment. All twin
pairs were re-examined in 1999 for adherence to gluten-free diet, presence of the
rash or gastrointestinal symptoms and IgA antibodies to gliadin and endomysium.
The study has permission (number 27.10.98/98181) from the Ethical Committee of
Tampere University Hospital and every twin gave an informed consent in 1999.
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Hungarian coeliac disease patients (III)
The study included 139 unrelated Hungarian patients with either the skin (71 DH
patients) or the intestinal (68 cCD patients) form of gluten sensitivity who all had
biopsy-confirmed diagnosis. DH patients have been diagnosed by the presence of
a blistering rash and granular IgA deposits in the skin. They also underwent jejunal
biopsy at diagnosis and were investigated for serum endomysial antibodies. Coeliac
patients were diagnosed by jejunal biopsy according to the criteria of the ESPGAN
(88) and all were endomysial antibody positive. Samples were collected after
discussion with the patients/parents and with the approval of the Ethical Committee
of the Heim Pal Children’s Hospital, Budapest.
Coeliac disease patients from European Genetics Cluster (V)
Nine-hundred-and-eight families with gluten sensitive patients were recruited from
France, Italy, Norway, Sweden and the UK for a study of DQ2 negative patients.
The net result including the Finnish material of one hundred families was altogether
1008 families with 121 DQ2 negative index patients. The foreign patients fulfilled
the revised ESPGAN criteria (88) for the diagnosis and material obtained an approval
from the regional ethics committees for each participating centre and written informed
consent from every participating subject.
SAMPLES IN STUDY I
HLA region-linked microsatellite markers were studied in 131 chromosomes
from 49 Finnish families, in 51 patients with congenital adrenal hyperplasia
due to 21-hydroxylase deficiency, in 13 Finnish patients waiting for an unrelated
bone marrow transplant from a Finnish donor, in 8 Finnish patients waiting for an
unrelated bone marrow transplant from a non-Finnish donor, in 58 Finnish bone
marrow donors, and in 32 HLA reference cell lines.
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DNA EXTRACTION
Genomic DNA was extracted from whole blood by either the salting out procedure
(188) or by commercial kits (Pel-Freez Clinical Systems, Brown Deer, WI or Qiagen,
Hilden).
MICROSATELLITE MARKERS
Altogether nineteen microsatellite markers linked to the HLA region were typed. These
markers D6S276, D6S2239, D6S2225, D6S2223, D6S105, MOGc, D6S265, C3_2_11,
C2_4_4, MIB, MICA, TNFb, TNFa, D6S273, NOTCH4, DQCARII, DQCAR, G51152,
D6S291, are commonly used tools for HLA typing (66;69;189-191). Most of the markers
were located within the 3 Mb HLA region, but D6S291 was ~2 Mb centromeric from
HLA-DPB1; D6S2223, D6S2225 and D6S2239 in the HFE gene region, D6S105 ~2
Mb telomeric from the HLA-A and D6S276 ~6 Mb telomeric from the HLA-A (Fig. 10).
Variable combinations of microsatellite markers were used in different studies.
In addition, eight microsatellite markers from different chromosomes (D1S1589,
D9S158, D10S1213, D14S617, D15S642, D16S403, D17S1293 and D18S851) were
used for verification of twins genuine monozygosity in study II.
The standard amplification procedures were applied and the length of the PCR
products were estimated by single capillary electrophoresis ABI PRISM TM310 Genetic
Analyzer (Applied Biosystems, Foster City, CA). The TAMRA-labelled size standard
GeneScan-500 TAMRA or -2500 TAMRA (Applied Biosystems, Foster City, CA) was
simultaneously run with each sample to get allele size estimates. The microsatellite
alleles were given as arbitrary migration units and the standardisation between the
Figure 10. A map indicating the locations of nineteen typed microsatellite markers and their
relation to classical HLA loci. Most microsatellites are located within the 3 Mb segment in the
HLA region, but D6S291 is located ~2,5 Mb centromeric from DQB1, and D6S105 ~2 Mb
telomeric from HLA-A, D6S2223, D6S2225 and D6S2239 around the HFE region ~4.6 Mb
from HLA-A, and D6S276 ~6 Mb telomeric from HLA-A. The map is not on scale.
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studies was archieved by re-typing the same patients, as well as using national
and international CEPH-controls.
DETERMINATION OF HLA ALLELES (‘HLA TYPING’)
Commercial kits used for DQB1 typings were Dynal AllSet+TM SSP DQ ‘’low
resolution’’ (Dynal, Oslo) and LiPA-DQB1 kit (Innogenetics, Ghent). Two microsatellite
markers (DQCAR, DQCARII) in Finnish and three (DQCAR, DQCARII, G51152) (189)
in Hungarian samples were employed to deduce the DR;DQ haplotypes. More
detailed typing of HLA-A, -B, -DRB1-5, -DQA1, -DQB1 and -DPB1 alleles was done
by commercial kits by Innogenetics, Ghent; Dynal, Oslo; Olerup SSP, Saltsjöbaden
and PEL-FREEZ Clinical Systems, Brown Deer, WI.
Other typing methods utilised in the Finnish simplex families with gluten sensitive
patients have been described by Polvi et al (1996)(187), with 21-hydroxylase
deficiency family material described by Levo et al (1997)(192) and with patients
from France, Italy, Norway, Sweden and the UK by Karell et al (2003)(V).
HAPLOTYPING AND STATISTICAL ANALYSIS
Haplotypes were constructed from individual genotypes manually and by the
Genehunter 2.0 program (193). The Genehunter program was also used for Mendel
checking and for indicating possible recombinations.
The linkage disequilibrium between HLA alleles and microsatellite markers (study I)
was estimated from Finnish haplotypes using the Arlequin program package
version 1.1 by Schneider et al (1997)(194) http://anthropologie.unige.ch/arlequin.
The test is an extension of the Fisher exact test. Instead of enumerating all possible
contingency tables, a Markov chain is used to evaluate the probability. For the
actual test the chain length was set at 100 000 and the dememorization at 1000.
Evidence for the linkage disequilibrium was regarded as strong if the exact probability
obtained was p < 0.0001, weak but possible if 0.0001 < p < 0.01 and no linkage
disequilibrium was assumed if p > 0.01.
Estimation of probability that the assumed twins genuinely were monozygotic rather
than dizygotic ones (study II), was performed by calculating the number of
microsatellites used for identification by probability of 0.25 i.e. the sib pair is identical
by change. The casewise concordance rate, Cc, was estimated according to the
formula Cc=2C/(2C+D), where C stands for the number of pairs concordant and
D for discordant.
The Fisher exact two-tailed test was applied when comparing frequencies of alleles
either transmitted or never transmitted to affected sibs from DR3;DQ2 homozygous
parents (study IV). It was also used when comparing haplotype frequencies between
Finnish and Hungarian gluten sensitive patients (study III).
A simple binomial test was used to compare haplotype frequencies in DQ2 negative
patients (study V). A p-value <0.05 was considered significant.
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MICROSATELLITE MARKERS AS A PRACTICAL TOOL FOR HLA TYPING (I)
The determination of HLA alleles, often called ‘HLA typing’, by using either
commercial kits or standardised assays, is a relatively easy and reliable method
now used world-wide in clinical diagnostics in tissue typing laboratories. However,
in scientific research projects the emphasis is often directed to more economical,
faster and less DNA demanding methods, at least for an initial screening for possible
HLA association. Lin et al (1997) (189) demonstrated strong linkage disequilibrium
between HLA class II-linked microsatellite markers, DQCAR, DQCARII, and G51152,
and the HLA DR-DQ genotypes in the Japanese, Norwegians and New Guineas.
We examined if the same phenomenon was seen in the Finnish population. As the
genetic background of the Finns is assumed to be relatively narrow, we speculated
that microsatellite typing could be used  as an alternative method in the deduction
of at least the common, or major, HLA haplotypes in this population.
In addition to the three microsatellite markers studied by Lin et al (1997)(189), we
tested nine more markers (D6S276, MOGc, D6S265, MIB, TNFb, TNFa, D6S273,
NOTCH4, D6S291) distributed over the entire HLA region and even some of the
outskirts (Fig. 10). Most of the markers were found to be highly polymorphic when
tested in 131 unrelated chromosomes. Therefore they could be regarded as
informative genetic markers. Nearly all loci, except for the most distal D6S276 and
D6S291, showed evidence of strong linkage disequilibrium with the adjacent loci
(Study I, Fig. 2). In addition many microsatellite marker alleles appeared to be
associated with only certain HLA alleles (Study I, Fig. 3), indicating that they can be
used to deduce many HLA haplotypes.
To compare linkage disequilibrium between Finnish and non-Finnish chromosomes,
we estimated the degree of genetic variation in microsatellites associated with HLA-A,
-B, -DRB1-5 and -DQB1 matched haplotypes in 21 Finnish patients waiting for a bone
marrow transplant and their potential unrelated Finnish (n = 44; range 1 - 6 per patient)
and non-Finnish donors (n = 14, range: 1 - 3 per patient). The similarity between
Finnish haplotypes was striking after excluding the outermost markers (D6S276 and
D6S291) as 48% (21/44) of the patient - donor pairs were identical. The conservation
of the microsatellites was highest near the DR-DQ genes where there was practically
no variation at all (1 mismatch in 88 chromosomes). In Finnish patient - non-Finnish
donor pairs the variation was substantially higher as only one pair (7%) was identical
after excluding the outermost markers, but the linkage disequilibrium was still notably
strong within the DR-DQ region compared to other regions.
We concluded that the three markers located in the DR-DQ region, DQCAR, DQCARII
and G51152, can be used to deduce many common DR;DQ haplotypes in the
Finnish population (Table 6). This method has been later applied in additional
research projects for defining certain HLA-DRB1 alleles and also occasionally for
whole DR;DQ haplotypes (195). It also seems likely that many HLA-A and -B alleles
can be deduced from the microsatellite data but the large variation in alleles and
lower linkage disequilibrium may sometimes hamper the interpretation.
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Microsatellite typing is a relatively easy procedure with a simple PCR (polymerase
chain reaction) run and measuring the length of the PCR amplicon is now possible
to perform using highly automated apparatuses.
However it is unlikely that the actual HLA typing would be replaced by the
microsatellite method, since the HLA typing is a widely standardised and accredited
method used by co-operating international centres. It is also important to remember
that the HLA molecules as such are the crucial determinants for transplantation
matching. In principle, microsatellites could be applied for routine HLA typing as
extra markers or as the first screen for HLA identical siblings, but this would require
more detailed validation of the method. Also, due to a higher mutation rate in
microsatellite loci (196), their allelic differences may not always indicate a genuine
difference in the HLA genes.
SAME HLA HAPLOTYPES CONFER GENETIC SUSCEPTIBILITY TO BOTH
INTESTINAL AND DERMATOLOGICAL MANIFESTATION OF GLUTEN
SENSITIVITY (II, III)
The two main manifestations of gluten sensitivity are the intestinal form, here
called classical coeliac disease (cCD), and the dermatological form, dermatitis
herpetiformis (DH). DH patients have often been included in studies of coeliac
disease (170;197) in particular when coeliac disease is defined more broadly,
synonymous to gluten sensitivity, as is also done in the present thesis. This is
explained by similarities in environmental and genetic risk factors as well as in
symptoms (106). However there are some differences in opinion whether DH
patients should be included or not.
As the HLA-DQ is known to be the major genetic locus for susceptibility to gluten
sensitivity, we wanted to evaluate whether different clinical forms are determined
by differences in the HLA loci. First, concordance in monozygotic twins was estimated
to evaluate the relative contributions of genetic and environmental factors. Six pairs
Table 6. The specific allele combinations of DQCAR, DQCARII and G51152 microsatellite
markers are in linkage disequilibrium with HLA-DR and -DQ alleles and thus can be used to
deduce the DR;DQ haplotypes.
HAPLOTYPE DQCAR DQCARII G51152
DR3;DQ2 92 201/197/195 213/211
DR7;DQ2 106/114/112/110/108/92 215/217/213/211/209 211
DR1;DQ5 96 195/199 220/236
DR2;DQ5 96 199 211
DR6;DQ5 100 197 215
DR2;DQ6 96 197 220
DR6;DQ6 96 205/207 220/217/215
DR5;DQ7 110/112/114/116 183/185/191 211
DR4;DQ8 104 191/197 220/222
DR8;DQ4 92 195 192
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of monozygotic twins were found amongst 1292 probands with DH (II). Second, a
study on 25 sib pairs (III) discordant for the manifestation was done in order to
define the sharing of HLA haplotypes between siblings within each family. In addition,
85 concordant sib pairs (81 cCD-cCD and 4 DH-DH) were included for comparison.
We wanted to focus on the haplotype distribution especially in the families, since
the other factors, environmental and genetic, can be assumed to be substantially
more homogeneous in each family than in the standard case-control studies.
The basic clinical manifestation and HLA alleles of the six twin pairs are shown in
Table 7. Briefly, three pairs (pairs 1, 4, 5) were concordant for the manifestation of
DH, two (pairs 2 and 3) only for gluten sensitivity when defined as a more broad
entity (i.e. one sibling had DH, the other cCD). Finally, one of the six pairs was
discordant for any manifestation, one was affected by DH and cCD whereas the
other had no symptoms or any laboratory findings suggesting preclinical forms of
this disease. The follow-up period for the twins varied from 3 to 30 years. It is of
note that the discordant pair was followed for the shortest time. All the twins had
the HLA-DR and -DQ alleles associated with gluten sensitivity; one of the DH-DH
concordant pair was homozygous for DR4;DQ8 and the others were positive for
DR3;DQ2. Interestingly, the only discordant pair for gluten-sensitivity had no
homozygosity in any of the HLA risk loci, unlike all the other pairs. However, otherwise
there appeared to be no clear overall association between the HLA alleles and
clinical manifestation. Consequently, five of the six pairs were concordant with respect
to gluten-sensitivity, giving a casewise concordance rate of 0.91. Then again, the
more precise clinical manifestation varied. One of the major problems in twin studies
is that there may be positive bias for concordant twins, in particular, when no
systematic population-based approach is performed. Nevertheless, our figures can
be regarded as reliable, since the casewise concordance rate in a thus-far only
population-level screening study by Greco and co-workers (2002)(53) was 0.86,
surprisingly similar to ours. These two studies indicate that the concordance rate in
gluten sensitivity is very high for a multifactorial disease. In most other multifactorial
diseases the rate has been reported to be around 0.25 - 0.46 (Table 3). Thus it can
be concluded that the role of genes in gluten sensitivity is crucial - alternatively, it is
possible to speculate that the figures can be explained by a very low variation in an
environment.
The effect of HLA genes on the manifestation was also studied in families (study
III). The distribution of haplotypes inherited identical by state (IBS) was similar
between concordant and discordant sib pairs (study III) (Table 8). The distribution
of non-shared HLA haplotypes in the 11 discordant pairs, who shared only one
haplotype IBS, suggested that no predominant haplotype was enriched in or missing
from either group. So, the other haplotype may not modify the manifestation. All
patients were found to have the typical predisposing HLA types, the only exception
was a single DH patient. It should be noted that originally these families were selected
based on having at least two affected siblings. This material may consequently be
enriched by various major genetic and environmental susceptibility factors which
may mask possible minor effects by other locus within HLA on the clinical outcome.
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Gender/birth year
DQ2/DQ8/other
DRB1
DQA1
DQB1
Siblings A B A B A B
Disease/age at dg DH/26 DH/27 DH/23 cCD/25 DH/27 cCD/31
Gender/birth year
DQ2/DQ8/other
DRB1
DQA1
DQB1
Siblings A B A B A B
Disease/age at dg DH/23 DH/24 DH/29 DH/54 DH/38,cCD/37 no disease
F/58
M/70 F/38
DQ2/other
Twin pair 3
Twin pair 4 Twin pair 5
02,0301
DQ2/2
02,0301
02
DQ2/other
DQ2/other
M/58
02,0604
05
05 05
0301 0301,1201 0301,1301
05
DQ2/2
05,0102
0301
0302
DQ8/8
02
Twin pair 6
0401 0301,1201
Twin pair 1 Twin pair 2
F/65
0301
F/51
Table 7. The information of the six monozygotic twin pairs, their gender and birth year, HLA
status and clinical data of individual twins (A and B).
To extend the above results, obtained from the Finnish families, a set of
Hungarian patients with cCD or DH was studied. All the Hungarian patients
carried at least one of the known predisposing haplotypes: DR3;DQ2, DR4;DQ8,
or DQ2 in trans. The distribution of HLA phenotypes was very similar in the
cCD and DH groups, thus supporting the family study. However, a statistically
significant difference between the DH and cCD groups was noted; the DR3;DQ2/
DR5;DQ7 combination was more common in the DH patients than in the cCD
patients (26.8% vs. 8.8%, respectively; p= 0.008 by Fisher’s exact test). In
other words, DH patients had a double dose of DQA1*05 allele more frequently
than the cCD patients.
The double dose of certain HLA alleles may have a stronger effect on DH, but
the genuine value of this finding must be left open, since this could also reflect
solely the differences in haplotype frequencies between the two study
populations. There are obviously many genetic differences between the Finnish
and Hungarian populations, although the languages are distantly related. DH
F = female, M = male, DH = dermatitis herpetiformis, cCD = classical coeliac disease, dg = diagnosis
Table 8. The distribution of the identical by state (IBS) haplotypes did not differ between
the discordant (cCD-DH) and the concordant sib pairs (cCD-cCD or DH-DH).
n % n % n %
2 IBS 14 56 48 59 3 75
1 IBS 11 44 33 41 1 25
0 IBS 0 0 0 0 0 0
cCD-DH cCD-cCD DH-DH
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in Hungary is a relatively common disorder and usually seen in paediatric cases,
whereas in Finland it is found mainly in adults (106). A peculiar detail is that the
one discordant twin pair in study II was the only pair not having a double dose
of DQA1*05.
Our results will close down the debate of possible differences in HLA between
the intestinal and dermatological manifestations of gluten sensitivity. The
haplotypes are not only molecularly similar as suggested by earlier case-control
studies (198;199) but they are often indeed identical as could be demonstrated
by the present family study. The very high concordance rate in monozygotic
twins and HLA similarity even in discordant sib pairs gives the impression of a
limited number of genetic factors to gluten sensitivity. However, the few twins
found to be discordant clearly demonstrate that environmental factors, in
addition to dietary gluten, and small genetic differences between twins still
have a detectable effect.
A lot of speculation has been reported about environmental factors influencing
the development of coeliac disease. In addition to the primary role of gluten,
adenovirus has been suggested as one potential factor. It has segments
extremely similar in amino acid sequence to gluten, but the genuine role of
adenovirus is not clear (94). Exposure to different antigens leads inevitably to
a variable set of T cells which may play a role in the onset of disease. Indeed
different sets of T cell receptors were reported in twins even concordant for CD
(200). Also customs in breast feeding (201) and the time of introducing solid
food to children may have an effect. This was evident in Sweden in the 80’s
with a sudden increase in prevalence of paediatric cases with gluten sensitivity
when cereals were added into commercial baby food (202). At the same time
the age of onset was increased in many other countries (203). Now we are
able to witness a similar increase in the number of CD patients among Saharawi
refugees, who are fed by cereals instead of their traditional diet (98) indicating
that it is not only the timing but also the amount of gluten that affects the
onset, maybe by breaking oral tolerance.
EXTENDED B8;DR3;DQ2 HAPLOTYPE PREDISPOSE TO COELIAC DISEASE (IV)
The DR3;DQ2 haplotype is known to predispose to coeliac disease and there is
both genetic and functional evidence that the HLA-DQ molecules are the primary
susceptibility factors (121). However, although the class II genes are obviously the
major associated locus to various autoimmune disease, data have emerged that
the other HLA-linked genes may modify their effect on susceptibility (48;204;204;205).
Also the overwhelmingly strong evidence in the whole genome screens for HLA
and its flanking regions in coeliac disease have stimulated detailed searches of the
HLA region in hope of finding novel influencing susceptibility genes. We wanted to
address this question by dissecting the DR3;DQ2 haplotypes in CD families and
evaluating their relative effects on susceptibility. The homozygous parent TDT-type
of approach was used (206) for the first time in coeliac studies by Polvi et al
(1997)(207) in which evidence for DPB1*0101 was obtained. In study IV this
approach was systematically applied; fourteen DR3;DQ2 homozygous parents were
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found and the segregation of the DR3;DQ2 haplotypes, dissected by microsatellite
typing, were traced to the affected offspring.
The DR3;DQ2 positive haplotypes transmitted to affected children were very
conserved and the majority (15/21, 71%) had alleles HLA-A*01, -B*08 and
-DPB1*0101. One third showed conservation even up to loci D6S2239, D6S2225
or D6S2223, which are all located even 4.6 Mb telomeric from HLA-A (Fig. 10). In
DR3;DQ2 haplotypes never inherited by the affected children, the conservation
was restricted only to the region between G51152 (close to HLA-DQ) and MIB (next
to HLA-B). The conservation near DR-DQ genes was expected since the selection
was done based on the DR3;DQ2 positivity. Statistically the most significant
difference between transmitted and non transmitted haplotypes was the frequency
of HLA-A*01 (p = 0.007) but additionally suggestive evidence (p = 0.02 - 0.04)
could be found for D6S265*181, C3_2_11*216 and C2_4_4*222 alleles (Fig. 11).
The results for the DR3;DQ2 homozygous parents clearly indicated that there are
differences between DR3;DQ2 haplotypes. The majority of the transmitted
haplotypes had alleles HLA-A*01, B*08, DRB1*03, DQ2, and often also DPB1*0101,
that is, they formed the well-known ancestral haplotype called 8.1 AH. The peculiar
8.1 AH is exceptional in many ways; it is very conserved and associated in addition
to coeliac disease with e.g. type 1 diabetes, myastenia gravis and systemic lupus
erythematosus, common variable immunodeficiency and IgA deficiency (31).
However it is also one of the most common haplotypes in Caucasoids. Hence it is
either expected to be relatively young haplotype or to have some survival advantages.
Both may be true; the survival advantages have been shown from controversial
Figure 11. The comparison between the DR3;DQ2 haplotypes transmitted (n = 21) and
non-transmitted (n = 7) from homozygous parents to coeliac offspring. The most common
allele in each locus of the transmitted haplotypes was chosen as the index size and their
frequencies were compared. Black line: the frequency in transmitted haplotypes; Dotted
line: the frequency in non-transmitted haplotypes. The transmitted haplotypes remained
conserved longer than the non-transmitted haplotypes. Statistically the most significant
difference was at HLA-A*01 (p = 0.007) and suggestive difference for microsatellite alleles
D6S265*181, C3_2_11*216 and C2_4_4*222 ( p = 0.02-0.04).
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studies where 8.1 AH was over-represented in Caucasian nonagenarian males and
the haplotype seemed be advantageous in early foetal life (208).
The strong linkage disequilibrium in AH 8.1 may hide the locations of other
predisposing factors for CD in addition to DQ2. Our results pinpoint most strongly
to the class I region but as the Finnish population is known for its strong founder
effect the linkage disequilibrium may cover exceptionally large regions and other
risk factor(s) may be situated anywhere within or near HLA. In a recent Italian
segregation study of DR3;DQ2 haplotypes the most significant differences between
transmitted and non transmitted haplotypes were seen more centromeric than in
study IV, in microsatellite markers MIB, MICA and MICB (Bolognese E, Karell K,
Percopo S, Coto I, Greco L, Mantovani V, Suoraniemi E, Partanen J, Mustalahti K,
Mäki M and Momigliano-Richiardi P, accepted by Tissue Antigens). Those markers
are in the vicinity of HLA-B and the highly transmitted alleles are all markers of the
ancestral 8.1 haplotype, thus supporting our results. Also a recent multicentre
European study indicated  weakly that a group of neighbouring loci between D6S273
and MIB possibly may be associated with an increased risk although no single locus
with significant evidence was found (Louka AS, Moodie SJ, Karell K, Bolognesi E,
Ascher H, Greco L, Momigliano P, Partanen J, Ciclitira PJ, Sollid LM and the European
Genetics Cluster on Coeliac Disease, accepted by Human Immunology). Hence,
the final proof for the existence as well as the for the location of the putative novel
susceptibility gene in HLA require more systematic mapping studies.
Many candidate genes in the HLA region have already been tested for association
with CD. However, they are mostly sporadic studies and suffer from the case-control
type of approach where selection of proper controls, due to high linkage
disequilibrium in HLA, is difficult. The HLA-DP locus has shown to be associated
with CD, but obviously due to linkage disequilibrium with DQ, in Finnish (187),
Norwegian (209) and French patients (152), whereas no association between DP
and CD was seen in Ashkenazi Jews (210). In the USA DPw2 showed a negative
association with DH and thus a protecting effect was suggested (211). Also the
reported association of TAP1 and TAP2 genes, which are located in the HLA class
II region (Fig. 2), seems to be secondary and a consequence of linkage
disequilibrium (152;212;213).
More attention has been given to telomeric side with class III and I loci. Next to the
TNFa  gene, which has a role in immunological regulation and inflammation lies a
microsatellite shown to be associated with CD in the Irish population, possibly
independently of the A1;B8;DR3;DQ2 haplotype (214). The same allele showed
association in Finnish patients but after comparing the association with haplotype-
matched controls the difference vanished (215). Also an unequal distribution of
heat-shock protein 70 (HSP70-2) alleles seems to result from a strong association
with HLA-DR3 and not primarily with CD (216). The A5.1 allele of the MICA gene,
has been shown to carry  a nucleotide insertion causing it to become a secreted
form of the MICA molecule. The predominant expression of MICA molecules on
gastrointestinal epithelial makes it an interesting candidate: it could inhibit the
activation of gd  T cells or NK cells (217) thus inflicting the onset of CD or at least
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causing milder symptoms. The A5.1 allele was claimed to be associated with silent
CD independently of the HLA class II alleles (218). Controversially, it has been
shown to be a part of the extended DR3;DQ2 haplotype (219;220). Also allele 3 of
a microsatellite D6S2223 located telomeric of the HLA class I region (Fig. 10) was
found to reduce susceptibility in a recessive manner to both CD and type 1 diabetes
(221). The association of D6S2223*3 to some nearby gene raised enthusiasm, but
not our study neither the study from the EU Cluster (Louka AS, Moodie SJ, Karell K,
Bolognesi E, Ascher H, Greco L, Momigliano P, Partanen J, Ciclitira PJ, Sollid LM
and the European Genetics Cluster on Coeliac Disease, accepted by Human
Immunology) have confirmed the first results.
The many genetic studies of coeliac disease have concluded HLA-DQ to be the
single confirmed susceptibility factor. The strong linkage disequilibrium complicates
studies in the HLA region and hence more effort has been put into other regions
and replication studies of potential non-HLA candidate loci. Most probably numerous
different loci affect the development of coeliac disease. The affected loci may also
vary between populations or manifestation types. To reveal these predisposing
loci, subdivision of patients according to stricter clinical phenotypes may be helpful.
The basis of subgrouping in CD can be e.g. clinical manifestation type (silent/full/DH),
age of onset, or sex. Also, subgrouping according to the HLA status should be of
interest. By this way Holopainen et al (2001)(222) found stronger evidence for linkage
to chromosomes 5q and 11q in multiplex CD families with at least one DH patient,
whereas chromosome 2q was more strongly linked in families with only cCD patients.
The role of HLA-DQ2 as a susceptibility factor was suggested to be stronger in
females than males. These results call for further studies in which more strictly
defined clinical subgroups of CD can be interesting to study specially in non-HLA
regions.
ONLY A FEW PATIENTS WITH COELIAC DISEASE LACK THE KNOWN HLA
SUSCEPTIBILITY ALLELES. A MULTINATIONAL EUROPEAN STUDY (V)
Multinational European Genetics Cluster on Coeliac Disease enabled the largest
ever collection of DQ2 negative coeliac patients. Patients were collected from Finland,
France, Italy, Norway, Sweden and the UK. From a total of no less than 1008 families,
121 DQ2 negative patients were found. About half (n = 60) of these carried the
DQ8 heterodimer, known to be a predisposing marker in DQ2 negative CD (121),
and most of the remaining patients (n = 61) had either the DQB1*02 or DQA1*05
allele which encode for the half of the DQ2 heterodimer. Finally, there were only
four (0.4%) patients who did not have any alleles known to predispose to coeliac
disease. The results definitely indicate that the HLA susceptibility to CD is restricted
to DQ2 and DQ8 alleles and individuals negative for these alleles have only a very
low risk to develop CD.
Previously published cases of patients negative for both DQ2 and DQ8 heterodimers
have had one part of the DQ2 heterodimer (150;210;223-225) with only nine
exceptions (140;155;160;226;227)(Table 9). The similarity in these nine patients
has been the over-represented HLA-DQ6 (DQA1*01;DQB1*06), which was seen in
6/9 patients. We did not observe an excess of DQ6 instead 20/61 DQ2 and DQ8
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negative patients carried the DQ5 (DQA1*01;DQB1*05) molecule which has
previously been claimed to be a predisposing factor (150) as well as a protective
one (155). We also noticed an excess of DQ8 homozygous patients (29/60), but
the frequencies varied greatly between populations. However, it is intriguing that
there are no published papers reporting a surplus of patients heterozygous for
DR4;DQ8/DR3;DQ2 if both of these DQ types indeed confer a risk independently.
The four patients negative for the known susceptibility genes did not have any
obvious similarities in symptoms, age of diagnosis, or HLA alleles (Table 10); thus,
they cannot suggest novel susceptibility factors within the HLA region. They may
represent phenocopies, i.e. cases with a genuinely different genetic background.
Although strong emphasis was laid on the accurate clinical data in the collaborative
study, we must also question the correctness of the diagnoses. Also possible mix
up with the samples can not be definitely ruled out. It is notable, that some other
disorders have similar symptoms to CD and the biopsies are often open to
interpretation.
Population DRB1 DQA1 DQB1 Reference
Spanish 13,1501 0102 0602,0604 Spurkland et al  1992
Spanish 13,08 0103,0401 0603,0402 Spurkland et al  1992
French 07,08 0201,0401 0303,0402 Djilali-Saiah et al  1994
Swedish 07,08 0201,04 0303,04 Ploski et al  1996
Swedish 0404,14 0301,0101 0304,0503 Ploski et al  1996
Finnish 13 0103 0603,0603/7 Polvi et al 1998
Finnish 1302,0801/6 0101/2/4,0401 0604,0402 Polvi et al 1998
Spanish 13011,08 0102,0601 0604,0301 Polvi et al 1998
Spanish 15011 - 0602/3 Garrote et al  2000
Table 10. Genetic and clinical data from the four unique coeliac patients without HLA-DQ2,
-DQ8 or either allele encoding DQ2 molecule found in the multinational European study.
Table 9. The published coeliac patients without the HLA-DQ2, -DQ8 or either allele encoding
the DQ2 molecule.
CD = coeliac disease
Patients Italy 24 Italy 25 Italy 26 UK 8
DRB1 14,01 0804,0102 0401,0701 08,01
DQA1 01,0104 0401,0101 0303,0201 0401,01
DQB1 05,05 0402,0501 0301,0303 04,0501
Age at onset 1 year Asymptomatic 1,5 years 50 years
Age at diagnosis 2 years 6 years 2 years 50 years
Family history none Sibling with CD, Sibling with CD Sibling with CD
family screening
Symptoms Diarrhoea, Asymptomatic Diarrhoea, vomiting, Diarrhoea
failure to thrive, failure to thrive,
vomiting abdominal pain
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No new predisposing risk factors within HLA was revealed by this European
collaboration. No association was seen with HLA class I alleles, HLA-A or -B, in the
patients with solely the DQA1*05 or DQB1*02 part of DQ2. Only HLA-B*44 and
perhaps B*13 were enriched but this may be due to linkage disequilibrium with
DR7. No indication of previously described association of DPB1*0101 (207;228) or
DPB1*0301 (229) alleles were noted either. Also the DRB4*- and DRB1*04- alleles
among patients were apparently equally distributed, each population however having
its own common alleles.
This study of DQ2 negative patients revealed no new information about other possible
risk factors located within the HLA region, but confirmed the reported results of the
strong importance of DQ2 and the milder effect of DQ8. We have to accept that
DQ2 and DQ8 are the major predisposing molecules for coeliac disease. Also,
even either one of the alleles, DQA1*05 or DQB1*02, encoding for the DQ2 molecule
may be sufficient alone. As patients without these alleles are extremely rare, it is
possible to use the HLA-DQ typing to exclude CD in risk families. The use of
DQ typing in routine diagnostics has been tested by our group (230) and has given
encouraging results. This kind of genetic testing in risk groups may become more
justified in the future if the high prevalence figures, many associated disorders and
increased lymphoma risk in undiagnosed individuals prove to be correct.
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CONLUDING REMARKS
In the present thesis it was formally demonstrated by the twin study that the gluten
sensitivity has a strong genetic component. The concordance rate was very high,
0.91. This figure is extremely similar to a recently published rate based on a
population study. We also confirmed that intestinal and dermatological coeliac
disease, dermatitis herpetiformis, appear to have the same genetic background,
as the monozygotic twins could develop either manifestation with the same set of
genes. In addition, we studied sib pairs who were discordant for the manifestation
type and they too shared the predisposing DQ alleles and gave no evidence that
the HLA haplotypes would have an effect on variation in clinical manifestation.
These results strongly indicate that from a genetic point of view, intestinal coeliac
disease and dermatitis herpetiformis should be regarded as different manifestations
of one disease entity.
In spite of intensive studies, only a very limited number of predisposing genes for
coeliac disease are known. The only firmly established locus is still the HLA-DQ.
The European Genetics Cluster on Coeliac Disease collected 1008 families for
genetic analysis and we were able to show that 90% of the index cases had genes
encoding the HLA-DQ2 molecules, 5% had genes for DQ8 and most of the rest the
DQA1*05 or DQB1*02 allele i.e. either allele for the DQ2 molecule. Only four
genetically unique patients were left. Hence, the HLA typing can be used for genetic
diagnostics. However the predisposing effect of HLA genes has been estimated to
be only about 40% of the total genetic risk. Hence, there must be numerous unknown
genetic factors with minor predisposing effects elsewhere in the genome, maybe
also within or near the HLA region, hidden behind the strong linkage disequilibrium
as actually was suggested by the present segregation study of DR3;DQ2 haplotypes.
However the putative novel HLA-linked risk locus remains to be mapped.
The incidence of coeliac disease, including its silent and non-typical forms, may be
surprisingly high in European populations. The manifestations may substantially
vary from classical enteropathy to osteopenia or even to autoimmunity. To avoid
these diseases, an effective combination of genetical, immunological and clinical
diagnostics should become available. The present thesis provides further scientific
evidence that due to the extremely strong association with certain alleles, the HLA-DQ
determination might be one useful part of the diagnostics. It remains to be seen
when another predisposing gene with a milder effect will be located.
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